Endothelial atypical cannabinoid receptor: Do we have enough evidence?

British Journal of Pharmacology

Volumn 171, Issue 24, 2014, Pages 5573-5588

  Bondarenko, Alexander I ^a,b  

^a BOGOMOLETZ INSTITUTE OF PHYSIOLOGY   (Ukraine)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ACTIVATED POTASSIUM CHANNEL; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR; GPR18 RECEPTOR; GPR55 RECEPTOR; O 1918; PERTUSSIS TOXIN; RIMONABANT; UNCLASSIFIED DRUG; 1,3-DIMETHOXY-5-METHYL-2-(3-METHYL-6-(1-METHYLETHENYL)-2-CYCLOHEXEN-1-YL)BENZENE; ANISOLE DERIVATIVE; CANNABINOID RECEPTOR AGONIST; CYCLOHEXANE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ARTERY DILATATION; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL CULTURE; NONHUMAN; REVIEW; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; PHYSIOLOGY; VASODILATATION;

ANISOLES; CANNABIDIOL; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; CYCLOHEXANES; ENDOTHELIAL CELLS; HUMANS; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; RECEPTORS, G-PROTEIN-COUPLED; VASODILATION;

EID: 84919363015     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12866     Document Type: Review

References (108)

1. Alexander SP, (2012). So what do we call GPR18 now? Br J Pharmacol 165: 2411-2413.
2. Alexander SP, Kendall DA, (2007). The complications of promiscuity: endocannabinoid action and metabolism. Br J Pharmacol 152: 602-623.
3. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
4. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ligand-gated ion channels. Br J Pharmacol 170: 1582-1606.
5. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Ion channels. Br J Pharmacol 170: 1607-1651.
6. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013d). The Concise Guide to PHARMACOLOGY 2013/14: Nuclear hormone receptors. Br J Pharmacol 170: 1652-1675.
7. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013f). The Concise Guide to PHARMACOLOGY 2013/14: Transporters. Br J Pharmacol 170: 1706-1796.
8. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013g). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
9. Alsuleimani YM, Hiley CR, (2013). Mechanisms of vasorelaxation induced by oleoylethanolamide in the rat small mesenteric artery. Eur J Pharmacol 702: 1-11.
10. 2+ exchange is critical for vascular endothelial growth factor-mediated extracellular signal-regulated kinase (ERK) 1/2 activation and angiogenic functions of human endothelial cells. J Biol Chem 286: 37919-37931.
11. Baker D, Pryce G, Davies WL, Hiley CR, (2006). In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 27: 1-4.
12. Barana A, Amorõs I, Caballero R, Gõmez R, Osuna L, Lillo MP, et al. (2010). Endocannabinoids and cannabinoid analogues block cardiac hKv1.5 channels in a cannabinoid receptor-independent manner. Cardiovasc Res 85: 56-67.
13. Baranowska-Kuczko M, MacLean MR, Kozlowska H, Malinowska B, (2012). Endothelium-dependent mechanisms of the vasodilatory effect of the endocannabinoid, anandamide, in the rat pulmonary artery. Pharmacol Res 66: 251-259.
14. Baur R, Gertsch J, Sigel E, (2013). Do N-arachidonyl-glycine (NA-glycine) and 2-arachidonoyl glycerol (2-AG) share mode of action and the binding site on the β2 subunit of GABAA receptors? PeerJ 1: e149.
15. Bondarenko A, (2004). Sodium-calcium exchanger contributes to membrane hyperpolarization of intact endothelial cells from rat aorta during acetylcholine stimulation. Br J Pharmacol 143: 9-18.
16. +-ATPase is involved in the sustained ACh-induced hyperpolarization of endothelial cells from rat aorta. Br J Pharmacol 149: 958-965.
17. Bondarenko A, Waldeck-Weiermair M, Naghdi S, Poteser M, Malli R, Graier WF, (2010). GPR55-dependent and -independent ion signalling in response to lysophosphatidylinositol in endothelial cells. Br J Pharmacol 161: 308-320.
18. +: effects of enalapril and tempol. Clin Exp Pharmacol Physiol 39: 608-613.
19. Bondarenko AI, Sagach VF, (1997). Caffeine-induced electrical responses of intact endothelial cells. Neurophysiology 29: 156-161.
20. + channels in endothelial cells. Pflugers Arch 461: 177-189.
21. + channels. Pflugers Arch 462: 245-255.
22. 2+ entry into endothelial cells and activates BK channels independently of G-protein coupled receptors. Br J Pharmacol 169: 933-948.
23. Booz GW, (2011). Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med 51: 1054-1061.
24. Bosier B, Muccioli GG, Hermans E, Lambert DM, (2010). Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. Biochem Pharmacol 80: 1-12.
25. Brandes RP, Popp R, Ott G, Bredenkotter D, Wallner C, Busse R, et al. (2002). The extracellular regulated kinases (ERK) 1/2 mediate cannabinoid-induced inhibition of gap junctional communication in endothelial cells. Br J Pharmacol 136: 709-716.
26. Brown AJ, Daniels DA, Kassim M, Brown S, Haslam CP, Terrell VR, et al. (2011). Pharmacology of GPR55 in yeast and identification of GSK494581A as a mixed-activity glycine transporter subtype 1 inhibitor and GPR55 agonist. J Pharmacol Exp Ther 337: 236-246.
27. 1 receptor-deficient mice. Hypertension 39: 251-257.
28. Caldwell MD, Hu SS, Viswanathan S, Bradshaw H, Kelly ME, Straiker A, (2013). A GPR18-based signaling system regulates IOP in murine eye. Br J Pharmacol 169: 834-843.
29. Chaytor AT, Martin PE, Evans WH, Randall MD, Griffith TM, (1999). The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J Physiol 520 (Pt 2): 539-550.
30. Console-Bram L, Brailoiu E, Brailoiu GC, Sharir H, Abood ME, (2014). Activation of GPR18 by cannabinoid compounds: a tale of biased agonism. Br J Pharmacol 171: 3908-3917.
31. 2+ entry by preventing STIM1-Orai1 interaction. J Cell Sci 126: 879-888.
32. Fleming I, Schermer B, Popp R, Busse R, (1999). Inhibition of the production of endothelium-derived hyperpolarizing factor by cannabinoid receptor agonists. Br J Pharmacol 126: 949-960.
33. Fouad AA, Albuali WH, Al-Mulhim AS, Jresat I, (2013). Cardioprotective effect of cannabidiol in rats exposed to doxorubicin toxicity. Environ Toxicol Pharmacol 36: 347-357.
34. Garcia JG, Wang P, Liu F, Hershenson MB, Borbiev T, Verin AD, (2001). Pertussis toxin directly activates endothelial cell p42/p44 MAP kinases via a novel signaling pathway. Am J Physiol Cell Physiol 280: C1233-C1241.
35. Gasperi V, Dainese E, Oddi S, Sabatucci A, Maccarrone M, (2012). GPR55 and its interaction with membrane lipids: comparison with other endocannabinoid-binding receptors. Curr Med Chem 20: 64-78.
36. + channels. J Pharmacol Exp Ther 328: 351-361.
37. Harris D, McCulloch AI, Kendall DA, Randall MD, (2002). Characterization of vasorelaxant responses to anandamide in the rat mesenteric arterial bed. J Physiol 539: 893-902.
38. Hassan S, Eldeeb K, Millns P, Bennett A, Alexander S, Kendall D, (2014). Cannabidiol enhances microglial phagocytosis via transient receptor potential (TRP) channel activation. Br J Pharmacol 171: 2426-2439.
39. 2+ signaling and NFAT activation. FASEB J 23: 183-193.
40. Herradon E, Martin MI, Lopez-Miranda V, (2007). Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. Br J Pharmacol 152: 699-708.
41. Hiley CR, Hoi PM, (2007). Oleamide: a fatty acid amide signaling molecule in the cardiovascular system? Cardiovasc Drug Rev 25: 46-60.
42. Hill AJ, Jones NA, Smith I, Hill CL, Williams CM, Stephens GJ, et al. (2014). Voltage-gated sodium (Na) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se. Neurosci Lett 566: 269-274.
43. Ho WS, Hiley CR, (2003a). Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. Br J Pharmacol 138: 1320-1332.
44. 2+ influx. Br J Pharmacol 139: 585-597.
45. Ho WS, Hiley CR, (2004). Vasorelaxant activities of the putative endocannabinoid virodhamine in rat isolated small mesenteric artery. J Pharm Pharmacol 56: 869-875.
46. Ho WS, Yeung SYM, (2009). Novel G-protein-coupled receptors in rat arteries: potential targets for N-arachidonoyl glycine? Proc Br Pharmacol Soc 7: 060P.
47. Hoi PM, Hiley CR, (2006). Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor. Br J Pharmacol 147: 560-568.
48. Hoi PM, Visintin C, Okuyama M, Gardiner SM, Kaup SS, Bennett T, et al. (2007). Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide (VSN16) in the rat. Br J Pharmacol 152: 751-764.
49. 2 receptors. Proc Natl Acad Sci U S A 96: 14136-14141.
50. Jeong HJ, Vandenberg RJ, Vaughan CW, (2010). N-arachidonyl-glycine modulates synaptic transmission in superficial dorsal horn. Br J Pharmacol 161: 925-935.
51. Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA, et al. (2007). The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 152: 825-831.
52. Kargl J, Balenga N, Parzmair GP, Brown AJ, Heinemann A, Waldhoer M, (2012). The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55. J Biol Chem 287: 44234-44248.
53. + currents in rat dorsal root ganglion neurons. Brain Res 1062: 39-47.
54. Kohler R, Brakemeier S, Kuhn M, Degenhardt C, Buhr H, Pries A, et al. (2001). Expression of ryanodine receptor type 3 and TRP channels in endothelial cells: comparison of in situ and cultured human endothelial cells. Cardiovasc Res 51: 160-168.
55. Kohno M, Hasegawa H, Inoue A, Muraoka M, Miyazaki T, Oka K, et al. (2006). Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. Biochem Biophys Res Commun 347: 827-832.
56. Kozlowska H, Baranowska M, Schlicker E, Kozlowski M, Laudanski J, Malinowska B, (2007). Identification of the vasodilatory endothelial cannabinoid receptor in the human pulmonary artery. J Hypertens 25: 2240-2248.
57. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K, (2008). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 105: 2699-2704.
58. Liu B, Song S, Jones PM, Persaud SJ, (2014). GPR55: from orphan to metabolic regulator? Pharmacol Ther doi: 10.1016/j.pharmthera.2014.06.007. http://dx.doi.org/10.1016/j.pharmthera.2014.06.007
59. Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyannis A, et al. (2000). Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 346 (Pt 3): 835-840.
60. Lopez-Miranda V, Dannert MT, Herradon E, Alsasua A, Martin MI, (2010). Cytochrome P450 pathway contributes to methanandamide-induced vasorelaxation in rat aorta. Cardiovasc Drugs Ther 24: 379-389.
61. Lu VB, Puhl HL 3rd, Ikeda SR, (2012). N-arachidonyl glycine (NAGly) does not activate G protein-coupled receptor 18 (GPR18) signaling via canonical pathways. Mol Pharmacol 83: 267-282.
62. MacIntyre J, Dong A, Straiker A, Zhu J, Howlett SE, Bagher A, et al. (2014). Cannabinoid and lipid-mediated vasorelaxation in retinal microvasculature. Eur J Pharmacol 735C: 105-114.
63. Mangmool S, Kurose H, (2011). G(i/o) protein-dependent and -independent actions of Pertussis Toxin (PTX). Toxins (Basel) 3: 884-899.
64. Marchenko SM, Sage SO, (1993). Electrical properties of resting and acetylcholine-stimulated endothelium in intact rat aorta. J Physiol 462: 735-751.
65. Marchenko SM, Sage SO, (1996). Calcium-activated potassium channels in the endothelium of intact rat aorta. J Physiol 492 (Pt 1): 53-60.
66. Martinez-Pinilla E, Reyes-Resina I, Onatibia-Astibia A, Zamarbide M, Ricobaraza A, Navarro G, et al. (2014). CB and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum. Exp Neurol 261C: 44-52.
67. 2 cannabinoid receptor-independent nitric oxide production in rabbit aortic endothelial cells. J Pharmacol Exp Ther 321: 930-937.
68. McHugh D, Hu SS, Rimmerman N, Juknat A, Vogel Z, Walker JM, et al. (2010). N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci 11: 44.
69. McHugh D, Page J, Dunn E, Bradshaw HB, (2012). Delta(9)-Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br J Pharmacol 165: 2414-2424.
70. Milman G, Maor Y, Abu-Lafi S, Horowitz M, Gallily R, Batkai S, et al. (2006). N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci U S A 103: 2428-2433.
71. 2 or EDG. Eur J Pharmacol 489: 21-27.
72. Mukhopadhyay S, Chapnick BM, Howlett AC, (2002). Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am J Physiol Heart Circ Physiol 282: H2046-H2054.
73. Nicholson RA, Liao C, Zheng J, David LS, Coyne L, Errington AC, et al. (2003). Sodium channel inhibition by anandamide and synthetic cannabimimetics in brain. Brain Res 978: 194-204.
74. Nishida M, Suda R, Nagamatsu Y, Tanabe S, Onohara N, Nakaya M, et al. (2010). Pertussis toxin up-regulates angiotensin type 1 receptors through Toll-like receptor 4-mediated Rac activation. J Biol Chem 285: 15268-15277.
75. Offertaler L, Mo FM, Batkai S, Liu J, Begg M, Razdan RK, et al. (2003). Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 63: 699-705.
76. O'Sullivan SE, Kendall DA, Randall MD, (2004). Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries. Br J Pharmacol 142: 435-442.
77. O'Sullivan SE, Kendall DA, Randall MD, (2005a). The effects of Delta9-tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide. Br J Pharmacol 145: 514-526.
78. O'Sullivan SE, Kendall DA, Randall MD, (2005b). Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta. Eur J Pharmacol 507: 211-221.
79. O'Sullivan SE, Sun Y, Bennett AJ, Randall MD, Kendall DA, (2009). Time-dependent vascular actions of cannabidiol in the rat aorta. Eur J Pharmacol 612: 61-68.
80. Overton HA, Fyfe MC, Reynet C, (2008). GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br J Pharmacol 153 (Suppl. 1): S76-S81.
81. Oz M, (2006). Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids. Pharmacol Ther 111: 114-144.
82. Parmar N, Ho WS, (2010). N-arachidonoyl glycine, an endogenous lipid that acts as a vasorelaxant via nitric oxide and large conductance calcium-activated potassium channels. Br J Pharmacol 160: 594-603.
83. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucl. Acids Res 42 (Database Issue): D1098-1106.
84. Pertwee RG, (2010). Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr Med Chem 17: 1360-1381.
85. Pertwee RG, Ross RA, Craib SJ, Thomas A, (2002). (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol 456: 99-106.
86. Randall MD, Kendall DA, (1997). Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation. Eur J Pharmacol 335: 205-209.
87. Randall MD, Alexander SP, Bennett T, Boyd EA, Fry JR, Gardiner SM, et al. (1996). An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem Biophys Res Commun 229: 114-120.
88. Randall MD, Harris D, Kendall DA, Ralevic V, (2002). Cardiovascular effects of cannabinoids. Pharmacol Ther 95: 191-202.
89. Robson PJ, (2013). Therapeutic potential of cannabinoid medicines. Drug Test Anal 6: 24-30.
90. Ross HR, Gilmore AJ, Connor M, (2009). Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine. Br J Pharmacol 156: 740-750.
91. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092-1101.
92. Ca. Am J Physiol Heart Circ Physiol 297: H1-H7.
93. Shapira M, Vogel Z, Sarne Y, (2000). Opioid and cannabinoid receptors share a common pool of GTP-binding proteins in cotransfected cells, but not in cells which endogenously coexpress the receptors. Cell Mol Neurobiol 20: 291-304.
94. Su JY, Vo AC, (2007). 2-Arachidonylglyceryl ether and abnormal cannabidiol-induced vascular smooth muscle relaxation in rabbit pulmonary arteries via receptor-pertussis toxin sensitive G proteins-ERK1/2 signaling. Eur J Pharmacol 559: 189-195.
95. Takenouchi R, Inoue K, Kambe Y, Miyata A, (2012). N-arachidonoyl glycine induces macrophage apoptosis via GPR18. Biochem Biophys Res Commun 418: 366-371.
96. Vang A, Mazer J, Casserly B, Choudhary G, (2010). Activation of endothelial BKCa channels causes pulmonary vasodilation. Vascul Pharmacol 53: 122-129.
97. Wagner JA, Varga K, Jarai Z, Kunos G, (1999). Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33: 429-434.
98. 1-receptor-triggered repression. J Cell Sci 121: 1704-1717.
99. White R, Hiley CR, (1997). A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery. Br J Pharmacol 122: 1573-1584.
100. White R, Hiley CR, (1998). The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery. Br J Pharmacol 125: 689-696.
101. White R, Ho WS, Bottrill FE, Ford WR, Hiley CR, (2001). Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. Br J Pharmacol 134: 921-929.
102. Wilhelmsen K, Khakpour S, Tran A, Sheehan K, Schumacher M, Xu F, et al. (2014). The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells. J Biol Chem 289: 13079-13100.
103. Ca channels: an update on their pharmacology and usefulness as cardiovascular targets. J Cardiovasc Pharmacol 61: 102-112.
104. Yang KH, Galadari S, Isaev D, Petroianu G, Shippenberg TS, Oz M, (2010). The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes. J Pharmacol Exp Ther 333: 547-554.
105. Yang YY, Lin HC, Huang YT, Lee TY, Hou MC, Wang YW, et al. (2007). Role of Ca2+-dependent potassium channels in in vitro anandamide-mediated mesenteric vasorelaxation in rats with biliary cirrhosis. Liver Int 27: 1045-1055.
106. Yin H, Chu A, Li W, Wang B, Shelton F, Otero F, et al. (2009). Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem 284: 12328-12338.
107. Zakrzeska A, Schlicker E, Baranowska M, Kozlowska H, Kwolek G, Malinowska B, (2010). A cannabinoid receptor, sensitive to O-1918, is involved in the delayed hypotension induced by anandamide in anaesthetized rats. Br J Pharmacol 160: 574-584.
108. Zhang X, Maor Y, Wang JF, Kunos G, Groopman JE, (2010). Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. Br J Pharmacol 160: 1583-1594.